Antivirals: Current state of the art

Future Virology

Volumn 3, Issue 4, 2008, Pages 393-405

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Approved antiviral; CMV; Experimental antiviral; HBV; HCV; HIV; HSV; Influenza virus; Poxvirus; VZV

Indexed keywords

3 DEAZANEPLANOCIN A; ACICLOVIR; ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BAY 57 1293; BENZIMIDAVIR; BENZODIAZEPINE DERIVATIVE; CANERTINIB; CIDOFOVIR; CMX 001; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FAMCICLOVIR; FAVIPIRAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IMATINIB; INTEGRASE INHIBITOR; PEGINTERFERON; PIRODAVIR; PLECONARIL; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RSV 604; SIALIDASE INHIBITOR; ST 246; T 705; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENTEROVIRUS; HEPATITIS B; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; NONHUMAN; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; SMALLPOX; VACCINIA VIRUS; VIRUS ENTRY; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

CYTOMEGALOVIRUS; ENTEROVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 3; ORTHOMYXOVIRIDAE; POXVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; SIMPLEXVIRUS; VARIOLA;

EID: 55949103581     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.4.393     Document Type: Review

References (51)

1. De Clercq E: The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6, 1001-1018 (2007).
2. Flexner C: HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6, 959-966 (2007).
3. De Clercq E: From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virol. 1, 709-715 (2006).
4. Ferir G, Kaptein S, Neyts J, De Clercq E: Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med. Virol. 18, 19-34 (2008).
5. Painter GR, Almond MR, Trost LC et al.: Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51, 3505-3509 (2007).
6. Deres K, Schröder CH, Paessens A et al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299, 893-896 (2003).
7. Deres K, Rübsamen-Waigmann H: Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV. Infection 27, S45-S51 (1999).
8. De Clercq E: Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5, 1015-1025 (2006).
9. von Itzstein M: The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6, 967-974 (2007).
10. Furuta Y, Takahashi K, Kuno-Maekawa M et al.: Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49, 981-986 (2005).
11. De Clercq E, Holy A: Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4, 928-940 (2005).
12. Magee WC, Aldern KA, Hostetler KY, Evans DH: Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 52, 586-597 (2008).
13. Yang G, Pevear DC, Davies MH et al.: An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139-13149 (2005).
14. Quenelle DC, Buller RML, Parker S et al.: Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51, 689-695 (2007).
15. Sbrana E, Jordan R, Hruby DE et al.: Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76, 768-773 (2007).
16. Yang H, Kim SK, Kim M et al.: Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379-387 (2005).
17. Reeves PM, Bommarius B, Lebeis S et al.: Disabling poxvirus pathogenesis by inhibition of Abi-family tyrosine kinases. Nat. Med. 11, 731-739 (2005).
18. Duraffour S, Snoeck R, Kremerová M et al.: Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob. Agents Chemother. 51, 4410-4419 (2007).
19. Quenelle DC, Collins DJ, Herrod BP et al.: Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob. Agents Chemother., 3940-3947 (2007).
20. Hostetler KY, Beadle JR, Trahan J et al.: Oral 1-O-octadecyl-2-[i O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res. 73, 212-218 (2007).
21. Quenelle DC, Prichard MN, Keith KA et al.: Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51, 4118-4124 (2007).
22. Chapman J, Abbott E, Alber DG et al.: RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51, 3346-3353 (2007).
23. Crute JJ, Grygon CA, Hargrave KD et al.: Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8, 386-391 (2002).
24. Kleymann G, Fischer R, Betz UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392-398 (2002).
25. Betz UA, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H: Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46, 1766-1772 (2002).
26. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G: Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antiviral Chem. Chemother. 18, 35-48 (2007).
27. Biswas S, Jennens L, Field HJ: The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 75, 30-35 (2007).
28. Liuzzi M, Kibler P, Bousquet C et al.: Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res. 64, 161-170 (2004).
29. Biswas S, Smith C, Field HJ: Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1. J. Antimicrob. Chemother. 60, 274-279 (2007).
30. Biswas S, Swift M, Field HJ: High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antiviral Chem. Chemother. 18, 13-23 (2007).
31. De Clercq E: Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyrimidine nucleoside analogues. Med. Res. Rev. 23, 253-274 (2003).
32. McGuigan C, Pathirana RN, Migliore M et al.: Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitros of varicella zoster virus. J. Antimicrob. Chemother. 60. 1316-1330 (2007).
33. Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R: Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 49, 1081-1086 (2005).
34. Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154-163 (2006).
35. Chou S, Marousek GI: Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82, 246-253 (2008).
36. Weber O, Bender W, Eckenberg P et al.: Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleoside compound in vivo. Antiviral Res. 49, 179-189 (2001).
37. Reefschläger J, Bender W, Hallenberger S et al.: Novel non-nucleoside inhibitors of cytomegalovirus (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48, 757-767 (2001).
38. Buerger J, Reefschläger J, Bender W et al.: A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75, 9077-9086 (2001).
39. De Clercq E, Naesens L: In search of effective anti-HHV-6 agents. J. Clin. Virol. 47, S82-S86 (2006).
40. Naesens L, Bonnafous P, Agut H, De Clercq E: Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J. Clin. Virol. 37(Suppl. 1), S69-S75 (2006).
41. Wolfe ND, Dunavan CP, Diamond J: Origins of major human infectious diseases. Nature 447, 279-283 (2007).
42. Gowen BB, Wong MH, Jung KH et al.: In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51, 3168-3176 (2007).
43. Bray M, Raymond JL, Geisbert T, Baker RO: 3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res. 55, 151-159 (2002).
44. Julander JG, Furuta Y, Shafer K, Sidwell RW: Activty of T-1106 in a hamster model of yellow fever virus infection. Antimicrob. Agents Chemother. 51, 1962-1966 (2007).
45. McCormick JB, King IJ, Webb PA et al.: Lacsa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314, 20-26 (1986).
46. De Palma AM. Pürstinger G, Wimmer E et al.: Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 14, 545-551 (2008).
47. De Clercq E: Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2, 704-720 (2004).
48. Leyssen P, De Clercq E, Neyts J: The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 69, 1461-1467 (2006).
49. Sun Y, Chung D-H, Chu Y-K, Jonsson CB, Parker WB: Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′ -triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 51, 84-88 (2007).
50. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M: The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6, 991-1000 (2007).
51. Borden EC, Sen GC, Uze G et al.: Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6, 975-990 (2007).